ALS Drug Slows Disease Progression in Long-Term Study
- A new drug, tofersen (Qalsody), is offering hope to individuals with amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene.
- Tofersen is an antisense oligonucleotide, designed to block the production of the mutated SOD1 protein.
- Recent data from a long-term study reveal that approximately one-quarter of participants experienced stabilization of their ALS symptoms and even showed improvements in grip strength and respiratory function...
New ALS Drug Stabilizes Decline, Shows Promise for Improved Strength and Mobility
Table of Contents
A new drug, tofersen (Qalsody), is offering hope to individuals with amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene. While SOD1-related ALS accounts for onyl about 2% of all ALS cases, tofersen represents a significant advancement, becoming the first approved treatment specifically targeting the underlying genetic cause of ALS.
targeting the Root Cause of SOD1-ALS
Tofersen is an antisense oligonucleotide, designed to block the production of the mutated SOD1 protein. Developed through pioneering research at Washington University in St. Louis (WashU Medicine) and by biotech companies Biogen and Ionis Pharmaceuticals,the drug received accelerated FDA approval in 2023 based on initial trial results demonstrating reduced neurodegeneration.
Long-Term Data Shows Stabilization and Potential Improvement
Recent data from a long-term study reveal that approximately one-quarter of participants experienced stabilization of their ALS symptoms and even showed improvements in grip strength and respiratory function over a three-year treatment period. this suggests tofersen can not only slow disease progression but perhaps restore some lost function.
Patient Story: rickey Malloy’s Experience
Rickey Malloy, a 41-year-old plumber diagnosed with SOD1-ALS in 2023, exemplifies the potential benefits of tofersen. After a challenging diagnostic journey, he was referred to the WashU Medicine ALS Center and began receiving monthly injections of the drug. “I’ve been on the drug two years now, and I feel pretty good,” Malloy shared. “I have far less muscle spasming and cramping…My physical therapy team has added more exercises,and even stairs are getting easier. I’m now building strength rather then just maintaining it.” Remarkably, Malloy’s condition improved enough to qualify for a total knee replacement, which he had previously been deemed ineligible for.
Understanding ALS and the Impact of Tofersen
ALS, also known as Lou Gehrig’s disease, affects approximately 20,000 people in the US, progressively destroying the nerve cells controlling muscle function. the average life expectancy for individuals with SOD1-ALS is typically two to three years from symptom onset.However, data from the tofersen trial indicate a prolonged survival rate, with at least half of the participants still alive nearly five years after the study began - substantially longer than the expected natural course of the disease.
Study Details and Findings
the phase 3 clinical trial involved 108 participants, with 46 completing follow-up assessments after 3.5 to 5.5 years. While a statistically significant difference wasn’t observed between those who started tofersen instantly versus those who switched from placebo after six months,the trends consistently favored earlier treatment.Researchers attribute this to the study design, which provided tofersen to all participants at the six-month mark, potentially diminishing the observable difference between groups.
Side Effects and Future Research
Common side effects of tofersen include headache, injection site pain, falls, back pain, and extremity pain. More serious neurological side effects, primarily inflammatory in nature, occurred in 9% of participants but were successfully managed with additional therapies. A new clinical trial is currently underway, investigating tofersen’s potential to prevent or delay the onset of SOD1-ALS in individuals known to carry the gene variant but who are currently asymptomatic.
Looking Ahead
“There’s variability in patient response to tofersen-it’s not a panacea for everyone,” notes Robert Bucelli, co-director of the WashU medicine ALS Center. “but for those patients who do have a significant response, the fact that they’re able to maintain the independence they had when they went on the drug is a miracle.” The development of tofersen represents a major step forward in ALS research, and the same antisense oligonucleotide approach is now being explored for other forms of ALS and neurodegenerative diseases.